still wait event
action lower forecast nippon shinyaku reduc target
price potenti return maintain
invest overview releas earn result februari
includ yoy fall op trigger rapid drop share price
fall op expect due one-tim payment relat raw
materi record previou year think bigger factor lack
updat compani key drug develop program bullish
consensu estim strong investor interest pipelin
may set expect high howev think recent share
price weak excess continu upbeat potenti valu
pipelin uptravi sale growth
catalysts/risk still wait start next clinic studi
inhibitor myelofibrosi develop us
result next develop plan duchenn muscular dystrophi
program accord compani next studi
start sometim result readi
spring think nippon shinyaku need show sign develop
progress allevi pipelin concern
valuat target price deriv ep
previous price-to-earnings previous base
averag forward price-to-earnings bloomberg estim last
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price feb upsid rate outperform target price analyst yen ting chen
profit tax
issuanc retir stock
net chang cash
number share mn
rais sale forecast key drug domest busi
vidaza zalutia ciali howev assum top-sel vidaza take cut
drug price due market expans re-pric rule exce
revenu doubl compani origin peak sale project
reduc forecast royalti receiv oversea sale uptravi
johnson johnson acquisit actelion sale growth uptravi slow
especi ex-u sale trend expect howev given uptravi
import part jnj acquisit continu optimist growth
enter maintain oversea peak sale estim reduc
ramp rate ex-u market lower royalti rate assumpt nippon
shinyaku actual quarterli royalti revenu slightli
estim also revis currenc assumpt
charl martineau pm univers toronto figur sale product new forecast
urinari disord caus bph
cancer chronic pain
dev
file
dev
royalti licens
charl martineau pm univers toronto figur sale product previou forecast
urinari disord caus bph
cancer chronic pain
dev
dev
dev
royalti licens
charl martineau pm univers toronto figur profit loss statement
profit tax
compani mention price
